European Medicines Agency (EMA) Continues Marketing Authorization Application (MAA) Review for Lymphoseek® Dec 19, 2013
Navidea Biopharmaceuticals Submits Supplemental New Drug Application (sNDA) for Lymphoseek® for Sentinel Lymph Node Detection in Patients with Head and Neck Cancer Dec 17, 2013
FDA Grants Fast Track Designation to Navidea Biopharmaceuticals’ Lymphoseek® for Sentinel Lymph Node Detection in Patients with Head and Neck Cancer Dec 10, 2013
Navidea Biopharmaceuticals Initiates Pivotal Phase 3 Registration Program of NAV5001 SPECT Imaging Agent for Parkinson’s Disease Dec 3, 2013
Navidea to Collaborate with University of Alabama–Birmingham on Clinical Study Evaluating the RIGS™ Monoclonal Antibody Targeting Agent Nov 26, 2013
Navidea Biopharmaceuticals Announces Issuance of New U.S. Patent Covering Formulation for Neuroimaging Agent, NAV5001 Nov 14, 2013
Navidea to Collaborate with University of California–San Francisco on Clinical Study Evaluating Manocept™ Platform Imaging Agent in Kaposi Sarcoma (KS) Patients Nov 13, 2013